Research programme: complement pathway inhibitors - Attune Pharmaceuticals
Latest Information Update: 07 Mar 2017
At a glance
- Originator Attune Pharmaceuticals
- Class Small molecules
- Mechanism of Action Complement system protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 01 Mar 2017 Early research in Immunological disorders (Prevention) in USA (PO), before March 2017 (Attune Pharmaceuticals website)